12 completed, 3 unknown, 2 terminated, 2 withdrawn. 19 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 12, Unknown 3, Terminated 2, Withdrawn 2 |
| Phase 2 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Liver Disease: new trials by email Literature Review of Liver Disease trials Research Report on Liver Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. triopifexor, Placebo - Liver Disease | Phase 1 | Completed | Novartis Pharmaceuticals | 89 | 2020-05-29 | 2022-02-09 |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems Azacitidine, Pevonedistat - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 1 | Completed | Takeda | 17 | 2019-07-10 | 2024-09-05 |
| Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients Elafibranor - Hepatic Impairment, Liver Disease | Phase 1 | Completed | Genfit | 30 | 2018-12-12 | 2019-08-22 |
| Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study Caffeine citrate - Liver Disease | Phase 1 | Withdrawn | University of Birmingham | 2018-03-01 | 2018-04-19 | |
| Using Covered Stent of Diameter of 7mm in TIPS the stent of diameter of 7mm, the stent of diameter of 8mm - Liver Disease | Phase 1 | Unknown | Beijing Shijitan Hospital, Capital Medical University | 216 | 2015-08-01 | 2015-09-04 |
| The Effect of Probiotics on Non Alcoholic Fatty Liver Disease BioFemale - Liver Disease | Phase 1 | Terminated | Rabin Medical Center | 38 | 2013-02-01 | 2016-04-08 |
| A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan conivaptan hydrochloride - Liver Disease | Phase 1 | Completed | Cumberland Pharmaceuticals | 17 | 2011-04-01 | 2014-05-02 |
| Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease Lovaza (omega-3-acid ethyl ester), Corn oil - Liver Disease, Short Bowel Syndrome | Phase 1 / Phase 2 | Withdrawn | Boston Children's Hospital | 2011-01-01 | 2017-06-22 | |
| Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis conventional therapy plus MenSC transplantation, Conventional therapy plus placebo treatment - Liver Cirrhosis, Fibrosis | Phase 1 / Phase 2 | Unknown | S-Evans Biosciences Co., Ltd. | 50 | 2010-10-01 | 2012-06-07 |
| A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941 ASP1941 - Liver Disease | Phase 1 | Completed | Astellas Pharma Inc | 16 | 2010-05-01 | 2010-10-07 |
| Hepatocyte Matrix Implant Study Hepatocyte matrix implantation - Liver Disease, Liver Cirrhosis | Phase 1 | Unknown | Baermed | 10 | 2009-07-01 | 2011-04-12 |
| Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function conivaptan hydrochloride - Liver Disease, Hyponatremia | Phase 1 | Completed | Cumberland Pharmaceuticals | 26 | 2009-02-01 | 2014-05-02 |
| Hepatic Impairment Study Sorafenib (Nexavar, BAY43-9006) - Liver Disease | Phase 1 | Completed | Bayer | 45 | 2009-01-01 | 2014-11-03 |
| A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects naproxcinod - Liver Disease | Phase 1 | Completed | NicOx | 24 | 2008-01-01 | 2011-06-17 |
| Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction RTA 402 - Liver Disease | Phase 1 / Phase 2 | Terminated | Biogen | 16 | 2007-04-30 | 2025-05-30 |
| A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency Autologous Expanded CD34+ Haemopoietic cells - Liver Disease | Phase 1 / Phase 2 | Completed | Imperial College London | 5 | 2006-01-01 | 2019-10-31 |
| Health Behavior Feedback Study for Veterans With Hepatitis C 3 session brief intervention with health behavior feedback, treatment as usual - Alcoholism, Alcohol Abuse | Phase 1 | Completed | University of Washington | 12 | 2003-12-01 | 2007-11-30 |
| Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant EBV-specific autologous CTL - Liver Disease, Lymphoproliferative Disorders | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 50 | 2002-05-01 | 2010-01-13 |
| Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction oxaliplatin - Liver Disease | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2000-07-01 | 2008-03-04 |
Liver Diseases (19) · Liver Cirrhosis (2) · Alcoholism (1) · Digestive System Diseases (1) · Fibrosis (1) · Hepatitis C (1) · Hyponatremia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoproliferative Disorders (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency (1) · Short Bowel Syndrome (1)
Digestive System Diseases (18) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Hemic and Lymphatic Diseases (2) · Alcohol-Related Disorders (1) · Blood-Borne Infections (1) · Bone Marrow Diseases (1) · Chemically-Induced Disorders (1) · Chronic Disease (1) · Communicable Diseases (1) · Disease Attributes (1) · Fatty Liver (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fibrosis (1)
conivaptan (2) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · Azacitidine (1) · Corn Oil (1) · Fish Oils (1) · Interferons (1) · Omacor (1) · Oxaliplatin (1) · Sorafenib (1) · Therapeutics (1) · Ursodeoxycholic Acid (1) · caffeine citrate (1) · ipragliflozin (1) · naproxen-n-butyl nitrate (1) · pevonedistat (1)
Cumberland Pharmaceuticals (2) · Astellas Pharma Inc (1) · Baermed (1) · Bayer (1) · Beijing Shijitan Hospital, Capital Medical University (1) · Biogen (1) · Boston Children's Hospital (1) · Genfit (1) · Imperial College London (1) · National Cancer Institute (NCI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · NicOx (1) · Novartis Pharmaceuticals (1) · Rabin Medical Center (1) · S-Evans Biosciences Co., Ltd. (1)
United States (13) · United Kingdom (2) · China (1) · Israel (1) · Spain (1) · Switzerland (1)
Art Wheeler, MD (2) · Charlie Xiang, Professor (1) · David Adams, MD (1) · Hemda Weiss, M.D. (1) · Jianli Xu, MD PhD (1) · Nagy Habib, ChM FRCS (1) · Tania M Davis Correale, PhD (1) · Thomas C. Marbury, MD (1) · Tom Jaksic, MD, PhD (1)
2018 (1)